Date: Tuesday, September 22, 2020
FREE TO REGISTER!
StimGuide, An Innovative Solution to Optimize TMS Treatments
Adoption of 3D Navigation with EMG in the Clinical Practice Setting
This session will provide an overview of the workflow for the StimGuide 3D Navigation System and how it can be used in the clinical setting to improve:
- Precise and consistent coil placement
- Quality control and consistency for both novice and expert TMS technicians
- Simplifying MT determination utilizing EMG option
Session Objectives: Upon completion of the presentation, the participant should have a clear understanding about how 3D navigation and EMG can be used in the clinical setting to optimize TMS treatments, and how it differs from other navigation systems that require an MRI. Specifically, the following aspects will be covered:
- Registration of treatment target(s) and how these can be recalled for subsequent treatment sessions to ensure reliable coil positioning for both novice and expert technicians.
- Positioning the coil in the pre-determined treatment target by aligning the 4 parameters (xy location, contact, tilt, & rotation) within the specified tolerances
- Utilizing EMG to facilitate rMT Determination
- Tracking and monitoring coil position in real-time to maintain consistent positioning during a treatment
- How StimGuide can be used as a quality management tool for clinical sites that have multiple technicians and treaters
CME is not provided for this Product Theater Webinar.
*Disclaimer: The content does not reflect the views and/or opinions of Clinical TMS Society or its members and is solely determined by the sponsor.
Foster, Lance C, MD
Dr. Lance Foster is a Child and Family Psychiatrist at Northwest Arkansas Psychiatry. He is Board Certified in General Psychiatry and also in Child and Adolescent Psychiatry by the American Board of Psychiatry and Neurology. He serves as an adjunct Associate Professor of Psychiatry at the University of Arkansas for Medical Sciences. Dr. Foster is a member of the Clinical TMS Society and provides TMS therapy for patients suffering from depression. Dr. Foster was the Chief Medical Officer and a staff psychiatrist at Ozark Guidance Center for 15 years. As a staff psychiatrist, he provided psychiatric care for preschool through adult, Therapeutic Day Treatment programs, and the Child and Adolescent residential program. Dr. Foster is professionally affiliated with the American Psychiatric Association, Arkansas Psychiatric Society, American Academy of Child and Adolescent Psychiatry, and the American College of Physician Executives.
Staley, Randall, MD
Dr. Randall Staley joined Northwest Arkansas Psychiatry in 2018. Dr. Staley is board certified in Child and Adolescent Psychiatry and Adult Psychiatry by the American Board of Psychiatry and Neurology. He has practiced primarily with children and adolescents for more than 10 years, working with ADHD and other issues in Northwest Arkansas. Dr. Staley is a member of the Clinical TMS Society and provides TMS therapy for patients suffering from depression.
Magstim is the Brains behind TMS. Magstim pioneered Transcranial Magnetic Stimulation technology over 25 years ago. In 2019, Magstim received FDA clearance for StimGuide, the first TMS navigation system developed specifically for the clinical setting. StimGuide provides simple, precise and consistent coil positioning using 4 parameters to guide you to your specific target. Also in 2019, Magstim received 510k clearance for the iTBS 3-minute protocol. In 2018, Magstim received FDA clearance for the Horizon Performance System, our next generation TMS Therapy offering, which features the Energy Recovery System, (ERS). The proprietary ERS software ensures consistent stimulation throughout a treatment with no pulse decay. Horizon is cleared for the 3-minute, 19-minute and 37.5 minute protocols and is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Magstim received its initial FDA 510 (k) clearance to market the Rapid2 Therapy System in 2015.